-
Je něco špatně v tomto záznamu ?
In vitro activity of carvacrol in combination with meropenem against carbapenem-resistant Klebsiella pneumoniae
EO. Köse
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- antibakteriální látky farmakologie MeSH
- beta-laktamasy * genetika MeSH
- Cercopithecus aethiops MeSH
- cymeny MeSH
- karbapenemy farmakologie MeSH
- Klebsiella pneumoniae * MeSH
- meropenem farmakologie MeSH
- mikrobiální testy citlivosti MeSH
- synergismus léků MeSH
- Vero buňky MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Carbapenem resistance observed in Klebsiella pneumoniae strains limits treatment options. Therefore, use of antibiotics combined with bioactive compounds may be an important strategy to control K. pneumoniae. The purpose of this study was to evaluate the activity of combination of carvacrol and meropenem on carbapenem-resistant K. pneumoniae (CRKP) strains. The presence of blaOXA-48 carbapenemase in all 25 CRKP strains was identified using the PCR technique. The combination of carvacrol and meropenem was tested for antimicrobial activity on CRKP strains. The minimum inhibitory concentrations of carvacrol and meropenem were detected within a range of 32-128 μg/mL using the broth microdilution method. Synergy between carvacrol and meropenem was observed on 8 of the 25 CRKP strains by checkerboard assay (FICI = 0.5) and confirmed by time-kill assay. According to the live-dead test results, the viability percentage of the cells exposed to synergistic combination was 35.47% at the end of 24 h. The membrane damage caused by the synergistic combination was spectrophotometrically measured (A = 0.21) and further confirmed by SEM analysis. According to the MTT assay, both carvacrol and meropenem did not show any statistically significant cytotoxic effect on Vero cells (p > 0.05). In conclusion, the results suggest that carvacrol and meropenem can act synergistically to inhibit the growth of CRKP.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22005994
- 003
- CZ-PrNML
- 005
- 20240416150931.0
- 007
- ta
- 008
- 220207s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12223-021-00908-7 $2 doi
- 035 __
- $a (PubMed)34729712
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Köse, Elif Odabaş $u Medical Laboratory Program, Vocational School of Health Services, Akdeniz University, Antalya, Turkey. elifkose@akdeniz.edu.tr $1 https://orcid.org/000000023943571X
- 245 10
- $a In vitro activity of carvacrol in combination with meropenem against carbapenem-resistant Klebsiella pneumoniae / $c EO. Köse
- 520 9_
- $a Carbapenem resistance observed in Klebsiella pneumoniae strains limits treatment options. Therefore, use of antibiotics combined with bioactive compounds may be an important strategy to control K. pneumoniae. The purpose of this study was to evaluate the activity of combination of carvacrol and meropenem on carbapenem-resistant K. pneumoniae (CRKP) strains. The presence of blaOXA-48 carbapenemase in all 25 CRKP strains was identified using the PCR technique. The combination of carvacrol and meropenem was tested for antimicrobial activity on CRKP strains. The minimum inhibitory concentrations of carvacrol and meropenem were detected within a range of 32-128 μg/mL using the broth microdilution method. Synergy between carvacrol and meropenem was observed on 8 of the 25 CRKP strains by checkerboard assay (FICI = 0.5) and confirmed by time-kill assay. According to the live-dead test results, the viability percentage of the cells exposed to synergistic combination was 35.47% at the end of 24 h. The membrane damage caused by the synergistic combination was spectrophotometrically measured (A = 0.21) and further confirmed by SEM analysis. According to the MTT assay, both carvacrol and meropenem did not show any statistically significant cytotoxic effect on Vero cells (p > 0.05). In conclusion, the results suggest that carvacrol and meropenem can act synergistically to inhibit the growth of CRKP.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antibakteriální látky $x farmakologie $7 D000900
- 650 _2
- $a karbapenemy $x farmakologie $7 D015780
- 650 _2
- $a Cercopithecus aethiops $7 D002522
- 650 _2
- $a cymeny $7 D000081007
- 650 _2
- $a synergismus léků $7 D004357
- 650 12
- $a Klebsiella pneumoniae $7 D007711
- 650 _2
- $a meropenem $x farmakologie $7 D000077731
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a Vero buňky $7 D014709
- 650 12
- $a beta-laktamasy $x genetika $7 D001618
- 655 _2
- $a časopisecké články $7 D016428
- 773 0_
- $w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 67, č. 1 (2022), s. 143-156
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34729712 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220207 $b ABA008
- 991 __
- $a 20240416150928 $b ABA008
- 999 __
- $a ok $b bmc $g 1757408 $s 1157147
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 67 $c 1 $d 143-156 $e 20211102 $i 1874-9356 $m Folia microbiologica $n Folia microbiol. (Prague) $x MED00011005
- LZP __
- $a Pubmed-20220207